KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) saw unusually-strong trading volume on Friday . Approximately 786,520 shares traded hands during trading, an increase of 177% from the previous session’s volume of 284,259 shares.The stock last traded at $11.26 and had previously closed at $9.27.

A number of brokerages recently commented on KALV. BTIG Research increased their price target on KalVista Pharmaceuticals from $18.00 to $27.00 and gave the company a “buy” rating in a research note on Monday. ValuEngine raised KalVista Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Wednesday, August 2nd.

The company’s 50-day moving average price is $8.00 and its 200 day moving average price is $8.00. The stock’s market capitalization is $109.37 million.

KalVista Pharmaceuticals (NASDAQ:KALV) last posted its quarterly earnings data on Thursday, September 14th. The specialty pharmaceutical company reported ($0.51) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.59) by $0.08. KalVista Pharmaceuticals had a negative return on equity of 60.42% and a negative net margin of 4,191.47%. The company had revenue of $0.10 million during the quarter. On average, equities research analysts anticipate that KalVista Pharmaceuticals, Inc. will post ($2.49) EPS for the current year.

In other KalVista Pharmaceuticals news, major shareholder Holdings A/S Novo sold 2,725,283 shares of the business’s stock in a transaction that occurred on Thursday, October 12th. The stock was sold at an average price of $9.64, for a total transaction of $26,271,728.12. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Rajeev M. Shah acquired 850,000 shares of the business’s stock in a transaction on Thursday, October 12th. The shares were purchased at an average price of $8.50 per share, with a total value of $7,225,000.00. The disclosure for this purchase can be found here. Over the last quarter, insiders have sold 2,937,830 shares of company stock valued at $27,833,571. 49.10% of the stock is owned by company insiders.

WARNING: This article was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this article on another website, it was copied illegally and reposted in violation of U.S. & international trademark and copyright legislation. The original version of this article can be accessed at https://www.thecerbatgem.com/2017/10/20/kalvista-pharmaceuticals-inc-kalv-sees-large-volume-increase.html.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, formerly Carbylan Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The Company has developed a portfolio of small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME).

Receive News & Stock Ratings for KalVista Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KalVista Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.